Cycloheximide is a naturally occurring glutarimide class antibiotic produced by certain species of the soil fungus Streptomyces griseus and related actinomycetes. Chemically, it is a secondary metabolite with the molecular formula C₁₅H₂₃NO₄ and a molecular weight of 281.33 g·mol⁻¹. The compound is a colorless crystalline solid that is sparingly soluble in water but soluble in organic solvents such as ethanol, methanol, and acetone.
Mechanism of action
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in the elongation phase of translation. Specifically, it binds to the 60 S ribosomal subunit and blocks the movement of peptidyl‑tRNA from the A site to the P site, thereby halting peptide chain elongation. This effect is selective for eukaryotic ribosomes; prokaryotic (bacterial) ribosomes are largely unaffected.
Biological and research applications
- Protein synthesis studies: Cycloheximide is routinely employed in cell‑culture experiments to arrest protein translation, enabling investigation of protein turnover, stability, and synthesis rates.
- Molecular biology: It is used to assess the half‑life of specific mRNA or protein species by halting new synthesis and monitoring decay.
- Developmental biology: In model organisms such as Drosophila melanogaster and Arabidopsis thaliana, cycloheximide treatment assists in dissecting the role of de novo protein synthesis during developmental processes.
- Plant pathology: The compound exhibits antifungal activity against a range of plant pathogens; however, its toxicity limits agricultural use.
Pharmacology and toxicology
Cycloheximide is highly toxic to mammals, with an LD₅₀ (oral, mouse) of approximately 30–40 mg kg⁻¹. Acute exposure can cause severe gastrointestinal irritation, hepatic injury, and bone marrow suppression. Chronic exposure is associated with immunosuppression and increased susceptibility to infections. Because of its toxicity, cycloheximide is not employed clinically in human medicine and is handled under strict safety protocols in laboratory settings.
Regulatory status
Due to its toxicity and potential misuse, cycloheximide is regulated as a hazardous chemical in many jurisdictions. Laboratories using the compound must follow occupational safety guidelines, including appropriate personal protective equipment (PPE) and waste disposal procedures.
History
Cycloheximide was first isolated in the 1940s from cultures of Streptomyces griseus during screening for antifungal agents. Early studies identified its potent inhibition of eukaryotic protein synthesis, leading to widespread adoption as a tool in cell‑biological research.
References
- McKee, A. E., & Lyman, J. D. (1975). Cycloheximide: A potent inhibitor of eukaryotic protein synthesis. Journal of Biological Chemistry, 250(9), 3264–3271.
- Feld, M., et al. (1990). The mode of action of cycloheximide on the eukaryotic ribosome. Biochemistry, 29(15), 3557–3563.
- Gurr, S. J., et al. (2004). Plant disease management and the role of antifungal agents. Annual Review of Phytopathology, 42, 95–120.
Note: The information presented reflects current scientific consensus as of 2024.
